- Home
- AMGN vs PGR Comparison
AMGN vs PGR Comparison
Compare AMGN & PGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PGR
- Stock Information
- Founded
- AMGN 1980
- PGR 1937
- Country
- AMGN United States
- PGR United States
- Employees
- AMGN N/A
- PGR N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PGR Property-Casualty Insurers
- Sector
- AMGN Health Care
- PGR Finance
- Exchange
- AMGN Nasdaq
- PGR Nasdaq
- Market Cap
- AMGN 150.8B
- PGR 120.8B
- IPO Year
- AMGN N/A
- PGR N/A
- Fundamental
- Price
- AMGN $334.19
- PGR $226.59
- Analyst Decision
- AMGN Hold
- PGR Buy
- Analyst Count
- AMGN 14
- PGR 15
- Target Price
- AMGN $313.31
- PGR $271.10
- AVG Volume (30 Days)
- AMGN 3.1M
- PGR 3.9M
- Earning Date
- AMGN 11-04-2025
- PGR 10-15-2025
- Dividend Yield
- AMGN 2.85%
- PGR 2.18%
- EPS Growth
- AMGN 65.12
- PGR 32.41
- EPS
- AMGN 12.93
- PGR 18.22
- Revenue
- AMGN $35,971,000,000.00
- PGR $85,166,000,000.00
- Revenue This Year
- AMGN $8.82
- PGR $12.51
- Revenue Next Year
- AMGN $1.84
- PGR $8.43
- P/E Ratio
- AMGN $25.85
- PGR $12.35
- Revenue Growth
- AMGN 10.56
- PGR 18.35
- 52 Week Low
- AMGN $253.30
- PGR $199.90
- 52 Week High
- AMGN $345.84
- PGR $292.99
- Technical
- Relative Strength Index (RSI)
- AMGN 61.60
- PGR 54.79
- Support Level
- AMGN $330.35
- PGR $220.80
- Resistance Level
- AMGN $345.49
- PGR $229.92
- Average True Range (ATR)
- AMGN 9.24
- PGR 4.47
- MACD
- AMGN 0.26
- PGR 2.04
- Stochastic Oscillator
- AMGN 68.68
- PGR 80.95
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.